<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel>
        <title>all</title>
        <link>http://all.link</link>
        <description>all</description>
        <lastBuildDate>Wed, 06 Mar 2024 18:45:00 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>nodejs</generator>
        <language>en</language>
        <item>
            <title><![CDATA[Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)]]></title>
            <link>https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302081008.html</link>
            <guid>https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302081008.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:45:00 GMT</pubDate>
            <description><![CDATA[HAMILTON, ON and BOSTON, March 6, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of...]]></description>
            <content:encoded><![CDATA[HAMILTON, ON and BOSTON, March 6, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of...]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Super Group Reports Financial Results for Fourth Quarter 2023 and Full Year 2023]]></title>
            <link>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:40:00 GMT</pubDate>
            <description><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></description>
            <content:encoded><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Super Group Reports Financial Results for Fourth Quarter 2023 and Full Year 2023]]></title>
            <link>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:40:00 GMT</pubDate>
            <description><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></description>
            <content:encoded><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Super Group Reports Financial Results for Fourth Quarter 2023 and Full Year 2023]]></title>
            <link>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240305972928/en/Super-Group-Reports-Financial-Results-for-Fourth-Quarter-2023-and-Full-Year-2023/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:40:00 GMT</pubDate>
            <description><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></description>
            <content:encoded><![CDATA[NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC” or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced fourth quarter 2023 and full year 2023 unaudited consolidated financial results. Neal Menashe, Chief Executive Officer of Super Group, commented: “We have made tremendous strides in 2023 and are delighted to have achieved an all-time revenue record of €1.4 billion,]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024]]></title>
            <link>http://www.businesswire.com/news/home/20240306083511/en/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024/?feedref=JjAwJuNHiystnCoBq_hl-YChnX-dlxR7bnql9VXy9e6PGT9SADxPkw1YVQTD4nSDrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3k94Xo7_69M07VeF2vYttikOoOnRBQBKcY2buBEMh6FZQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306083511/en/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024/?feedref=JjAwJuNHiystnCoBq_hl-YChnX-dlxR7bnql9VXy9e6PGT9SADxPkw1YVQTD4nSDrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3k94Xo7_69M07VeF2vYttikOoOnRBQBKcY2buBEMh6FZQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade co]]></description>
            <content:encoded><![CDATA[LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade co]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024]]></title>
            <link>http://www.businesswire.com/news/home/20240306083511/en/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</link>
            <guid>http://www.businesswire.com/news/home/20240306083511/en/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade co]]></description>
            <content:encoded><![CDATA[LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade co]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841312/0/en/New-Biomarker-Data-Add-Further-Evidence-Supporting-the-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-after-Gene-Therapy.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841312/0/en/New-Biomarker-Data-Add-Further-Evidence-Supporting-the-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-after-Gene-Therapy.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[CAMBRIDGE, Mass., March  06, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec). The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA. These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference (March 3-6, 2024).]]></description>
            <content:encoded><![CDATA[CAMBRIDGE, Mass., March  06, 2024  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec). The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA. These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference (March 3-6, 2024).]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Ocugen to Present at Investing in Cures Summit]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841310/0/en/Ocugen-to-Present-at-Investing-in-Cures-Summit.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841310/0/en/Ocugen-to-Present-at-Investing-in-Cures-Summit.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[MALVERN, Pa., March  06, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.]]></description>
            <content:encoded><![CDATA[MALVERN, Pa., March  06, 2024  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841289/0/en/Cognition-Therapeutics-Presents-Analyses-at-AD-PD-2024-Correlating-Proteomic-Findings-with-Treatment-Effect-of-CT1812-in-Alzheimer-s-Disease-Studies.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841289/0/en/Cognition-Therapeutics-Presents-Analyses-at-AD-PD-2024-Correlating-Proteomic-Findings-with-Treatment-Effect-of-CT1812-in-Alzheimer-s-Disease-Studies.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[PITTSBURGH, March  06, 2024  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's &amp; Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.]]></description>
            <content:encoded><![CDATA[PITTSBURGH, March  06, 2024  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's &amp; Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Ollie’s Bargain Outlet Holdings, Inc. Announces Fourth Quarter and Full-Year Fiscal 2023 Release Date and Conference Call Information]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841291/36273/en/Ollie-s-Bargain-Outlet-Holdings-Inc-Announces-Fourth-Quarter-and-Full-Year-Fiscal-2023-Release-Date-and-Conference-Call-Information.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841291/36273/en/Ollie-s-Bargain-Outlet-Holdings-Inc-Announces-Fourth-Quarter-and-Full-Year-Fiscal-2023-Release-Date-and-Conference-Call-Information.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[HARRISBURG, Pa., March  06, 2024  (GLOBE NEWSWIRE) -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) announced today that it will release its financial results for the fourth quarter and full-year fiscal 2023 on Wednesday, March 20, 2024, before the market opens. Following the release, at 8:30 a.m. Eastern Time, the Company’s management team will host a conference call to discuss its results.]]></description>
            <content:encoded><![CDATA[HARRISBURG, Pa., March  06, 2024  (GLOBE NEWSWIRE) -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) announced today that it will release its financial results for the fourth quarter and full-year fiscal 2023 on Wednesday, March 20, 2024, before the market opens. Following the release, at 8:30 a.m. Eastern Time, the Company’s management team will host a conference call to discuss its results.]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841294/0/en/Sensei-Biotherapeutics-to-Present-New-Preclinical-Data-at-Upcoming-Scientific-Conferences.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841294/0/en/Sensei-Biotherapeutics-to-Present-New-Preclinical-Data-at-Upcoming-Scientific-Conferences.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[BOSTON, March  06, 2024  (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.]]></description>
            <content:encoded><![CDATA[BOSTON, March  06, 2024  (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Abercrombie & Fitch Co. Reports Fourth Quarter and Full Year Results]]></title>
            <link>https://www.globenewswire.com/news-release/2024/03/06/2841295/0/en/Abercrombie-Fitch-Co-Reports-Fourth-Quarter-and-Full-Year-Results.html</link>
            <guid>https://www.globenewswire.com/news-release/2024/03/06/2841295/0/en/Abercrombie-Fitch-Co-Reports-Fourth-Quarter-and-Full-Year-Results.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[NEW ALBANY, Ohio, March  06, 2024  (GLOBE NEWSWIRE) -- Abercrombie &amp; Fitch Co. (NYSE: ANF) today announced results for the fourteen week fourth quarter and fifty-three week year ended February 3, 2024. These compare to results for the thirteen week fourth quarter and fifty-two week year ended January 28, 2023. Descriptions of the use of non-GAAP financial measures and reconciliations of GAAP and non-GAAP financial measures accompany this release.]]></description>
            <content:encoded><![CDATA[NEW ALBANY, Ohio, March  06, 2024  (GLOBE NEWSWIRE) -- Abercrombie &amp; Fitch Co. (NYSE: ANF) today announced results for the fourteen week fourth quarter and fifty-three week year ended February 3, 2024. These compare to results for the thirteen week fourth quarter and fifty-two week year ended January 28, 2023. Descriptions of the use of non-GAAP financial measures and reconciliations of GAAP and non-GAAP financial measures accompany this release.]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Reviews Are In: Cars.com 2024 Dealer of the Year Awards Recognize the Best Local Car-Shopping Experiences Across America]]></title>
            <link>https://www.prnewswire.com/news-releases/the-reviews-are-in-carscom-2024-dealer-of-the-year-awards-recognize-the-best-local-car-shopping-experiences-across-america-302081014.html</link>
            <guid>https://www.prnewswire.com/news-releases/the-reviews-are-in-carscom-2024-dealer-of-the-year-awards-recognize-the-best-local-car-shopping-experiences-across-america-302081014.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[Over 1 Million Consumer Reviews Show Responsiveness, Accountability Are Keys to Delivering Excellent Dealership Experience CHICAGO, March 6, 2024 /PRNewswire/ -- Car-shopping marketplace and dealer reputation site Cars.com® (NYSE: CARS) — home to more than 13 million dealership reviews,...]]></description>
            <content:encoded><![CDATA[Over 1 Million Consumer Reviews Show Responsiveness, Accountability Are Keys to Delivering Excellent Dealership Experience CHICAGO, March 6, 2024 /PRNewswire/ -- Car-shopping marketplace and dealer reputation site Cars.com® (NYSE: CARS) — home to more than 13 million dealership reviews,...]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Conagra Brands to Release Fiscal 2024 Third Quarter Earnings on April 4, 2024]]></title>
            <link>https://www.prnewswire.com/news-releases/conagra-brands-to-release-fiscal-2024-third-quarter-earnings-on-april-4-2024-302080858.html</link>
            <guid>https://www.prnewswire.com/news-releases/conagra-brands-to-release-fiscal-2024-third-quarter-earnings-on-april-4-2024-302080858.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[CHICAGO, March 6, 2024 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) will release its fiscal 2024 third quarter results on Thursday, April 4, 2024. A press release and supplemental materials, including pre-recorded remarks, will be issued that morning prior to a 30-minute live...]]></description>
            <content:encoded><![CDATA[CHICAGO, March 6, 2024 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) will release its fiscal 2024 third quarter results on Thursday, April 4, 2024. A press release and supplemental materials, including pre-recorded remarks, will be issued that morning prior to a 30-minute live...]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Riyadh Air and IBM Take Further Steps Forward in their Collaboration to Redefine Travel Experiences]]></title>
            <link>https://www.prnewswire.com/news-releases/riyadh-air-and-ibm-take-further-steps-forward-in-their-collaboration-to-redefine-travel-experiences-302081396.html</link>
            <guid>https://www.prnewswire.com/news-releases/riyadh-air-and-ibm-take-further-steps-forward-in-their-collaboration-to-redefine-travel-experiences-302081396.html</guid>
            <pubDate>Wed, 06 Mar 2024 18:30:00 GMT</pubDate>
            <description><![CDATA[RIYADH, Saudi Arabia, March 6, 2024 /PRNewswire/ -- IBM (NYSE: IBM) announced today the next steps in their collaboration with Riyadh Air, the digital-native airline currently scheduled to commence operations in early 2025, to revolutionize the airline's travel experiences. The airline...]]></description>
            <content:encoded><![CDATA[RIYADH, Saudi Arabia, March 6, 2024 /PRNewswire/ -- IBM (NYSE: IBM) announced today the next steps in their collaboration with Riyadh Air, the digital-native airline currently scheduled to commence operations in early 2025, to revolutionize the airline's travel experiences. The airline...]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Campbell Reports Second-Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:15:00 GMT</pubDate>
            <description><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></description>
            <content:encoded><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Campbell Reports Second-Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-Rc4vIAVcHHkbDcwJimU8QtrtlakeQ9hNboBqTAWIjTge3KWq9s9jif-UkBjBsFRyYAbRTSLTc1mgvhPlnaBA55M-oupQnbXnhKsYk8RmHF_kAy2gZikaX3QWV6xOvgFlA==</link>
            <guid>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-Rc4vIAVcHHkbDcwJimU8QtrtlakeQ9hNboBqTAWIjTge3KWq9s9jif-UkBjBsFRyYAbRTSLTc1mgvhPlnaBA55M-oupQnbXnhKsYk8RmHF_kAy2gZikaX3QWV6xOvgFlA==</guid>
            <pubDate>Wed, 06 Mar 2024 18:15:00 GMT</pubDate>
            <description><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></description>
            <content:encoded><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[United Natural Foods Names Giorgio Matteo Tarditi President and Chief Financial Officer]]></title>
            <link>http://www.businesswire.com/news/home/20240306555209/en/United-Natural-Foods-Names-Giorgio-Matteo-Tarditi-President-and-Chief-Financial-Officer/?feedref=JjAwJuNHiystnCoBq_hl-ed20Xeg3m02ke7wLHzR0vhC-PaDxm2AxJabicA7iw7ievRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZyOJkysC5Ezh0qTiBmuAAj_MB0k7bSxuNDrJ9ITS1Yyw==</link>
            <guid>http://www.businesswire.com/news/home/20240306555209/en/United-Natural-Foods-Names-Giorgio-Matteo-Tarditi-President-and-Chief-Financial-Officer/?feedref=JjAwJuNHiystnCoBq_hl-ed20Xeg3m02ke7wLHzR0vhC-PaDxm2AxJabicA7iw7ievRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZyOJkysC5Ezh0qTiBmuAAj_MB0k7bSxuNDrJ9ITS1Yyw==</guid>
            <pubDate>Wed, 06 Mar 2024 18:15:00 GMT</pubDate>
            <description><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today announced that Giorgio “Matteo” Tarditi has been named President and Chief Financial Officer (CFO), effective April 15. He succeeds John W. Howard, UNFI’s current Chief Financial Officer, who will leave the Company following a transition period. Sandy Douglas, CEO and President of UNFI, said: “Matteo is a proven executive who, over the course of his more than 26 years at GE, served as CFO]]></description>
            <content:encoded><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today announced that Giorgio “Matteo” Tarditi has been named President and Chief Financial Officer (CFO), effective April 15. He succeeds John W. Howard, UNFI’s current Chief Financial Officer, who will leave the Company following a transition period. Sandy Douglas, CEO and President of UNFI, said: “Matteo is a proven executive who, over the course of his more than 26 years at GE, served as CFO]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Campbell Reports Second-Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:15:00 GMT</pubDate>
            <description><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></description>
            <content:encoded><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Campbell Reports Second-Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240305047630/en/Campbell-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:15:00 GMT</pubDate>
            <description><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></description>
            <content:encoded><![CDATA[CAMDEN, N.J.--(BUSINESS WIRE)--Campbell Soup Company (NYSE:CPB) today reported results for its second-quarter fiscal 2024 ended January 28, 2024. CEO Comments “We once again delivered on our commitments, with a sequential improvement in volume trends and year-over-year operating margin expansion in both our Meals &amp; Beverages and Snacks divisions,” said Campbell's President and CEO, Mark Clouse. “We are excited about the anticipated completion of the acquisition of Sovos Brands which will br]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events]]></title>
            <link>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:02:00 GMT</pubDate>
            <description><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></description>
            <content:encoded><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events]]></title>
            <link>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:02:00 GMT</pubDate>
            <description><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></description>
            <content:encoded><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events]]></title>
            <link>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306129214/en/Xeris-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Events/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:02:00 GMT</pubDate>
            <description><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></description>
            <content:encoded><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital]]></title>
            <link>http://www.businesswire.com/news/home/20240306343645/en/Xeris-Refinances-Its-150M-Senior-Secured-Term-Loan-Facility-With-Hayfin-Capital/?feedref=JjAwJuNHiystnCoBq_hl-YChnX-dlxR7bnql9VXy9e6PGT9SADxPkw1YVQTD4nSDrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3k94Xo7_69M07VeF2vYttikOoOnRBQBKcY2buBEMh6FZQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306343645/en/Xeris-Refinances-Its-150M-Senior-Secured-Term-Loan-Facility-With-Hayfin-Capital/?feedref=JjAwJuNHiystnCoBq_hl-YChnX-dlxR7bnql9VXy9e6PGT9SADxPkw1YVQTD4nSDrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3k94Xo7_69M07VeF2vYttikOoOnRBQBKcY2buBEMh6FZQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down ano]]></description>
            <content:encoded><![CDATA[CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down ano]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Genius Sports Reports Fourth Quarter and Full-Year Results Above Expectations and Announces 2024 Outlook for Group Revenue Growth and Adj. EBITDA Margin Expansion]]></title>
            <link>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></description>
            <content:encoded><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[EVgo Inc. Reports Fourth Quarter and Full Year 2023 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></description>
            <content:encoded><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[REV Group, Inc. Reports Strong First Quarter Results, Provides Updated Fiscal 2024 Outlook]]></title>
            <link>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></description>
            <content:encoded><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Genius Sports Reports Fourth Quarter and Full-Year Results Above Expectations and Announces 2024 Outlook for Group Revenue Growth and Adj. EBITDA Margin Expansion]]></title>
            <link>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></description>
            <content:encoded><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[EVgo Inc. Reports Fourth Quarter and Full Year 2023 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></description>
            <content:encoded><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[REV Group, Inc. Reports Strong First Quarter Results, Provides Updated Fiscal 2024 Outlook]]></title>
            <link>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></description>
            <content:encoded><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Itron to Host Investor Day at Nasdaq MarketSite]]></title>
            <link>http://www.businesswire.com/news/home/20240306034118/en/Itron-to-Host-Investor-Day-at-Nasdaq-MarketSite/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306034118/en/Itron-to-Host-Investor-Day-at-Nasdaq-MarketSite/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LIBERTY LAKE, Wash.--(BUSINESS WIRE)--Itron to Host Investor Day at Nasdaq MarketSite]]></description>
            <content:encoded><![CDATA[LIBERTY LAKE, Wash.--(BUSINESS WIRE)--Itron to Host Investor Day at Nasdaq MarketSite]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Genius Sports Reports Fourth Quarter and Full-Year Results Above Expectations and Announces 2024 Outlook for Group Revenue Growth and Adj. EBITDA Margin Expansion]]></title>
            <link>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306837922/en/Genius-Sports-Reports-Fourth-Quarter-and-Full-Year-Results-Above-Expectations-and-Announces-2024-Outlook-for-Group-Revenue-Growth-and-Adj.-EBITDA-Margin-Expansion/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></description>
            <content:encoded><![CDATA[LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (NYSE:GENI) (“Genius Sports” or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal fourth quarter and full year ended December 31, 2023. “We are excited to report our eighth consecutive quarter of financial results above expectations, while demonstrating the increasing profitability of our business model]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[EVgo Inc. Reports Fourth Quarter and Full Year 2023 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306916176/en/EVgo-Inc.-Reports-Fourth-Quarter-and-Full-Year-2023-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></description>
            <content:encoded><![CDATA[LOS ANGELES--(BUSINESS WIRE)--EVgo Inc. (Nasdaq: EVGO) (“EVgo” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2023. Management will host a conference call today at 11:00 a.m. ET / 8:00 a.m. PT to discuss EVgo’s results and other business highlights. Revenue reached $50.0 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022, representing 83% year-over-year growth. For the full year 2023, revenue reached]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[REV Group, Inc. Reports Strong First Quarter Results, Provides Updated Fiscal 2024 Outlook]]></title>
            <link>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306949621/en/REV-Group-Inc.-Reports-Strong-First-Quarter-Results-Provides-Updated-Fiscal-2024-Outlook/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></description>
            <content:encoded><![CDATA[BROOKFIELD, Wis.--(BUSINESS WIRE)--REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2024 (“first quarter 2024”). Consolidated net sales in the first quarter 2024 were $586.0 million, representing an increase of 0.4% compared to $583.5 million for the three months ended January 31, 2023 (“first quarter 2023”). The increase in consolidated net sales was primarily due]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Itron to Host Investor Day at Nasdaq MarketSite]]></title>
            <link>http://www.businesswire.com/news/home/20240306034118/en/Itron-to-Host-Investor-Day-at-Nasdaq-MarketSite/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</link>
            <guid>http://www.businesswire.com/news/home/20240306034118/en/Itron-to-Host-Investor-Day-at-Nasdaq-MarketSite/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[LIBERTY LAKE, Wash.--(BUSINESS WIRE)--Itron to Host Investor Day at Nasdaq MarketSite]]></description>
            <content:encoded><![CDATA[LIBERTY LAKE, Wash.--(BUSINESS WIRE)--Itron to Host Investor Day at Nasdaq MarketSite]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Dalet and Veritone Reach Agreement to Distribute, Transact and Monetize Media Archives]]></title>
            <link>http://www.businesswire.com/news/home/20240306835377/en/Dalet-and-Veritone-Reach-Agreement-to-Distribute-Transact-and-Monetize-Media-Archives/?feedref=JjAwJuNHiystnCoBq_hl-d0q77hRjGWvCunvqSsMC5PkKuEqWGdtYcKRejd3o8qMqnKfqP6Z7nZVMLG-WqUNUuIFBOuQU34x9_qUrqnb9IFt3G9xeKEyIFKgj2nxZILuWb2_mZzaa2HVGkrPJ34F1Q==</link>
            <guid>http://www.businesswire.com/news/home/20240306835377/en/Dalet-and-Veritone-Reach-Agreement-to-Distribute-Transact-and-Monetize-Media-Archives/?feedref=JjAwJuNHiystnCoBq_hl-d0q77hRjGWvCunvqSsMC5PkKuEqWGdtYcKRejd3o8qMqnKfqP6Z7nZVMLG-WqUNUuIFBOuQU34x9_qUrqnb9IFt3G9xeKEyIFKgj2nxZILuWb2_mZzaa2HVGkrPJ34F1Q==</guid>
            <pubDate>Wed, 06 Mar 2024 18:00:00 GMT</pubDate>
            <description><![CDATA[PARIS & DENVER--(BUSINESS WIRE)--Dalet, a leading technology and service provider for media-rich organizations, and Veritone, Inc. (NASDAQ: VERI), a leader in designing human-centered AI solutions, today announced a technology partnership that integrates the Dalet Flex media workflow ecosystem with Veritone’s AI-powered Digital Media Hub (“DMH”), featuring its commerce and monetization capabilities. The integration enables a seamless workflow from content creation through production, curation,]]></description>
            <content:encoded><![CDATA[PARIS & DENVER--(BUSINESS WIRE)--Dalet, a leading technology and service provider for media-rich organizations, and Veritone, Inc. (NASDAQ: VERI), a leader in designing human-centered AI solutions, today announced a technology partnership that integrates the Dalet Flex media workflow ecosystem with Veritone’s AI-powered Digital Media Hub (“DMH”), featuring its commerce and monetization capabilities. The integration enables a seamless workflow from content creation through production, curation,]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Palantir to Unveil New Customers at Oversubscribed AIPCon]]></title>
            <link>http://www.businesswire.com/news/home/20240306456134/en/Palantir-to-Unveil-New-Customers-at-Oversubscribed-AIPCon/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306456134/en/Palantir-to-Unveil-New-Customers-at-Oversubscribed-AIPCon/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 17:59:00 GMT</pubDate>
            <description><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that more than 60 customers will showcase their work in Palantir’s Artificial Intelligence Platform (AIP) at its upcoming AIPCon, including the unveiling of 20+ new customers &amp; partners. The conference will be live streamed on Thursday, March 7, 2024 on Palantir’s YouTube channel. Palantir introduced AIP in mid-2023, and later that year introduced AIP Bootcamps, Palantir’s hands-on-keyboard acceleration program]]></description>
            <content:encoded><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that more than 60 customers will showcase their work in Palantir’s Artificial Intelligence Platform (AIP) at its upcoming AIPCon, including the unveiling of 20+ new customers &amp; partners. The conference will be live streamed on Thursday, March 7, 2024 on Palantir’s YouTube channel. Palantir introduced AIP in mid-2023, and later that year introduced AIP Bootcamps, Palantir’s hands-on-keyboard acceleration program]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Palantir to Unveil New Customers at Oversubscribed AIPCon]]></title>
            <link>http://www.businesswire.com/news/home/20240306456134/en/Palantir-to-Unveil-New-Customers-at-Oversubscribed-AIPCon/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</link>
            <guid>http://www.businesswire.com/news/home/20240306456134/en/Palantir-to-Unveil-New-Customers-at-Oversubscribed-AIPCon/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuWKa1ah7uC6RdZY8DBvigxR7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LPgxNjXHjsNmKaXEz4koEK2b14xTzGINXzl6XdKCab6Yw==</guid>
            <pubDate>Wed, 06 Mar 2024 17:59:00 GMT</pubDate>
            <description><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that more than 60 customers will showcase their work in Palantir’s Artificial Intelligence Platform (AIP) at its upcoming AIPCon, including the unveiling of 20+ new customers &amp; partners. The conference will be live streamed on Thursday, March 7, 2024 on Palantir’s YouTube channel. Palantir introduced AIP in mid-2023, and later that year introduced AIP Bootcamps, Palantir’s hands-on-keyboard acceleration program]]></description>
            <content:encoded><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that more than 60 customers will showcase their work in Palantir’s Artificial Intelligence Platform (AIP) at its upcoming AIPCon, including the unveiling of 20+ new customers &amp; partners. The conference will be live streamed on Thursday, March 7, 2024 on Palantir’s YouTube channel. Palantir introduced AIP in mid-2023, and later that year introduced AIP Bootcamps, Palantir’s hands-on-keyboard acceleration program]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Army Selects Palantir to Deliver TITAN Next Generation Deep-Sensing Capability in Prototype Maturation Phase]]></title>
            <link>http://www.businesswire.com/news/home/20240306864869/en/Army-Selects-Palantir-to-Deliver-TITAN-Next-Generation-Deep-Sensing-Capability-in-Prototype-Maturation-Phase/?feedref=JjAwJuNHiystnCoBq_hl-d0q77hRjGWvCunvqSsMC5PkKuEqWGdtYcKRejd3o8qMqnKfqP6Z7nZVMLG-WqUNUuIFBOuQU34x9_qUrqnb9IFt3G9xeKEyIFKgj2nxZILuWb2_mZzaa2HVGkrPJ34F1Q==</link>
            <guid>http://www.businesswire.com/news/home/20240306864869/en/Army-Selects-Palantir-to-Deliver-TITAN-Next-Generation-Deep-Sensing-Capability-in-Prototype-Maturation-Phase/?feedref=JjAwJuNHiystnCoBq_hl-d0q77hRjGWvCunvqSsMC5PkKuEqWGdtYcKRejd3o8qMqnKfqP6Z7nZVMLG-WqUNUuIFBOuQU34x9_qUrqnb9IFt3G9xeKEyIFKgj2nxZILuWb2_mZzaa2HVGkrPJ34F1Q==</guid>
            <pubDate>Wed, 06 Mar 2024 17:59:00 GMT</pubDate>
            <description><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that the Army Contracting Command – Aberdeen Proving Ground (ACC-APG) has awarded Palantir USG, Inc. — a wholly-owned subsidiary of Palantir Technologies Inc. — a prime agreement for the development and delivery of the Tactical Intelligence Targeting Access Node (TITAN) ground station system, the Army’s next-generation deep-sensing capability enabled by artificial intelligence and machine learning (AI/ML). The agre]]></description>
            <content:encoded><![CDATA[DENVER--(BUSINESS WIRE)--Palantir Technologies Inc. (NYSE: PLTR) today announced that the Army Contracting Command – Aberdeen Proving Ground (ACC-APG) has awarded Palantir USG, Inc. — a wholly-owned subsidiary of Palantir Technologies Inc. — a prime agreement for the development and delivery of the Tactical Intelligence Targeting Access Node (TITAN) ground station system, the Army’s next-generation deep-sensing capability enabled by artificial intelligence and machine learning (AI/ML). The agre]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[United Natural Foods, Inc. Reports Second Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</link>
            <guid>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fZYqiffDpHIASjea2DwvsWD1w08bW43U_zsPK9s38B4rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nBCddZ7R8TUqSJPYIyhFzD7nKdfLXU1CD0fwzlM5l88g==</guid>
            <pubDate>Wed, 06 Mar 2024 17:55:00 GMT</pubDate>
            <description><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></description>
            <content:encoded><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[United Natural Foods, Inc. Reports Second Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</link>
            <guid>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-fTiTHZ_tL7veK4k7YjFBuVdpTHRh3tVfOBYRO_O-9AIWJT50v2g3Ei-19qH0fyPszGrim8IhAkVNXbaI1AGppOzkqEXpa07kut2m9xviGvGqj7v8Jkr83IET3_poXLDvQ==</guid>
            <pubDate>Wed, 06 Mar 2024 17:55:00 GMT</pubDate>
            <description><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></description>
            <content:encoded><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[United Natural Foods, Inc. Reports Second Quarter Fiscal 2024 Results]]></title>
            <link>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</link>
            <guid>http://www.businesswire.com/news/home/20240306821992/en/United-Natural-Foods-Inc.-Reports-Second-Quarter-Fiscal-2024-Results/?feedref=JjAwJuNHiystnCoBq_hl-VJQ4LChRQEJgEJh9kC8YlSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu5nt7Rl4sG9WNhgpwCiv0iU</guid>
            <pubDate>Wed, 06 Mar 2024 17:55:00 GMT</pubDate>
            <description><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></description>
            <content:encoded><![CDATA[PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the second quarter of fiscal 2024 (13 weeks) ended January 27, 2024. Second Quarter Fiscal 2024 Performance (comparisons to second quarter fiscal 2023) Net sales decreased 0.5% to $7.8 billion Net loss of $15 million; Loss per diluted share (EPS) of $(0.25) Adjusted EBITDA decreased 29.3% to $128 million Adjusted EPS decreased to $0.07 Recent Financial and Op]]></content:encoded>
        </item>
    </channel>
</rss>